HIV/AIDS clinics and hospitals that participate in the 340B program are condemning drug manufacturer Gilead’s new conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies.
Ryan White Clinics for 340B Access (RWC-340B) said
…
Gilead late yesterday imposed conditions on 340B pricing on its branded hepatitis C treatments when covered entities use contract pharmacies. It is the 15th manufacturer to place restrictions on its 340B contract pharmacy program.
The policy, which applies to hospital
…
Janssen Pharmaceuticals is giving 340B entities refunds for overcharges on 14 NDCs during the third and fourth quarters of 2019, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
“The revisions were due to
…
Drug manufacturer AbbVie had added its best-selling cancer medicine Imbruvica to its restrictions on 340B pricing when hospitals use contract pharmacies, effective April 1.
AbbVie contractor 340B ESP posted a policy update from AbbVie on its website on March 1.
…
Nonprofit drug manufacturer Civica announced this morning that it plans to manufacture and distribute insulins that, once approved, will be available to people with diabetes at no more than $30 per vial and no more than $55 for a box
…
Thirteen congressional Democrats—eight senators and five representatives—asked Pharmaceutical Research and Manufacturers of America (PhRMA) to respond by March 8 to questions about “rapid price hikes affecting the vast majority of popular brand name drugs.”
Sens. Elizabeth Warren (Mass.) and Amy
…
340B provider and drug industry stakeholders joined yesterday in congratulating U.S. Public Health Service Lt. Cmdr. Emeka Egwim on his selection as Director of the U.S. Office of Pharmacy Affairs, the federal agency that runs the 340B drug pricing program.
…
In less than two years, brand drug companies that now must sell their products to 340B covered entities for a penny due to a history of price increases above inflation may have to start paying entities for their drugs instead
…
Drug manufacturer Merck is providing 340B covered entities with refunds for overcharges on 17 NDCs for purchases between Jan. 1 and March 31, 2019, the company says in a new public notice on the U.S. Health Resources and Services
…*Sign up for news summaries and alerts from 340B Report